The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)
Journal article
Gullestad, Lars, Ueland, Thor, Kjekshus, John, Nymo, Ståle H., Hulthe, Johannes, Muntendam, Pieter, McMurray, John J.V., Wikstrand, John and Aukrust, Pål. (2012). The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). American Heart Journal. 164(6), pp. 878 - 883. https://doi.org/10.1016/j.ahj.2012.08.021
Authors | Gullestad, Lars, Ueland, Thor, Kjekshus, John, Nymo, Ståle H., Hulthe, Johannes, Muntendam, Pieter, McMurray, John J.V., Wikstrand, John and Aukrust, Pål |
---|---|
Abstract | Galectin-3 is a new biomarker involved in inflammation and fibrogenesis and could therefore contribute to myocardial remodeling. We examined the prognostic value of baseline galectin-3 in a substudy involving approximately 30% of participants in the CORONA study. |
Year | 2012 |
Journal | American Heart Journal |
Journal citation | 164 (6), pp. 878 - 883 |
Publisher | Mosby Inc. |
ISSN | 0002-8703 |
Digital Object Identifier (DOI) | https://doi.org/10.1016/j.ahj.2012.08.021 |
Scopus EID | 2-s2.0-84870300941 |
Page range | 878 - 883 |
Research Group | Mary MacKillop Institute for Health Research |
Publisher's version | File Access Level Controlled |
Place of publication | United States |
Permalink -
https://acuresearchbank.acu.edu.au/item/858wq/the-predictive-value-of-galectin-3-for-mortality-and-cardiovascular-events-in-the-controlled-rosuvastatin-multinational-trial-in-heart-failure-corona
Restricted files
Publisher's version
(1 files)
110
total views0
total downloads0
views this month0
downloads this month